Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized clinical trial to evaluate the predictive accuracy of a gene in neoadjuvant chemotherapy for breast cancer
2005-000403-33Phase 4Active
- Sponsor
- GEICAM
- Start
- May 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of paclitaxel, epirubicin, fluorouracil and cyclophosphamide in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Pathologic complete response rate. Started May 2006; status: active.
02
Drugs
paclitaxelepirubicinfluorouracilcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000403-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000403-33.